SLXN insider transaction filings
Silexion Therapeutics Corp — 18 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-06-08. Screen SLXN transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-08 | 4 | Horenshtein Hadar Mirit — CFO and Secretary | Grant/award (A): 7,500 @ $0 | EDGAR |
| 2026-06-08 | 4 | Shirvan Mitchell — CSO and CDO | Grant/award (A): 6,000 @ $0 | EDGAR |
| 2026-06-08 | 4 | Hadar Ilan — Chairman and CEO, Director | Grant/award (A): 10,000 @ $0 | EDGAR |
| 2026-03-30 | 4 | Shirvan Mitchell — CSO and CDO | Sale (S): 22,818 @ $1.36 | EDGAR |
| 2026-02-25 | 4 | Noy Shlomo — Director | Grant/award (A): 9,091 @ $0 · Grant/award (A): 10,685 (derivative) @ $0 | EDGAR |
| 2026-02-23 | 4 | Horenshtein Hadar Mirit — CFO and Secretary | Grant/award (A): 49,726 @ $0 | EDGAR |
| 2026-02-23 | 4 | Abramov Dror Yosef — Director | Grant/award (A): 9,091 @ $0 · Grant/award (A): 10,685 (derivative) @ $0 | EDGAR |
| 2026-02-23 | 4 | Peled Amnon — Director | Grant/award (A): 7,576 @ $0 · Grant/award (A): 8,904 (derivative) @ $0 | EDGAR |
| 2026-02-23 | 4 | Lushi Avner — Director | Grant/award (A): 9,091 @ $0 · Grant/award (A): 10,685 (derivative) @ $0 | EDGAR |
| 2026-02-23 | 4 | Alon Ruth — Director | Grant/award (A): 9,091 @ $0 · Grant/award (A): 10,685 (derivative) @ $0 | EDGAR |
| 2026-02-23 | 4 | Shirvan Mitchell — CSO and CDO | Grant/award (A): 49,726 @ $0 | EDGAR |
| 2026-02-23 | 4 | Hadar Ilan — Chairman and CEO, Director | Grant/award (A): 64,350 @ $0 | EDGAR |
| 2026-01-27 | 4 | Levin Ilan — Director, 10% owner Moringa Sponsor, LP — 10% owner | Other (J): 5,550 @ $0 · Grant/award (A): 450,000 @ $4 · Other (J): 935 (derivative) @ $0 | EDGAR |
| 2025-12-31 | 4 | Abramov Dror Yosef — Director | Grant/award (A): 794 @ $0 · Grant/award (A): 935 (derivative) @ $0 | EDGAR |
| 2025-12-31 | 4 | Noy Shlomo — Director | Grant/award (A): 1,587 @ $0 · Grant/award (A): 1,872 (derivative) @ $0 | EDGAR |
| 2025-12-31 | 4 | Lushi Avner — Director | Grant/award (A): 1,587 @ $0 · Grant/award (A): 1,872 (derivative) @ $0 | EDGAR |
| 2025-12-31 | 4 | Peled Amnon — Director | Grant/award (A): 661 @ $0 · Grant/award (A): 780 (derivative) @ $0 | EDGAR |
| 2025-12-31 | 4 | Alon Ruth — Director | Grant/award (A): 794 @ $0 · Grant/award (A): 935 (derivative) @ $0 | EDGAR |
Recent 8-K events — Silexion Therapeutics Corp
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-21 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-08-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-13 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-13 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-10 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-04 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-03 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-07-31 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-07-29 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-21 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=SLXN returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →